uns- no deal, page-42

From thinking 'If i were Amgen...' :
Fully capitalize Unilife so our device supplier/investment is stable until b/e. Fixes balance sheet; gets uns pipeline moving; sends strong message to retail and institutional investors, analysts, brokers, financial journos, industry and prospective customers that unis is well and truly open for business; prevents an embarrassing need for more cash in 12-18 months time.

Hmm... will need to significantly reboot R&D for our new little device supplier. Given the awesome pace of med tech progress, without playing through Unilife there is far less point to being a corner stone investor. And if we don't they will be obsolete by the time they make a profit.

So ... normal forecast expenses, possible expansion, lines, etc etc, orbimed, r&d, ... 150m... say $5/sh... thats not outside ms range, or aanalysts range, 1b cap not unreasonable given pipeline, ip, value to us. Well now thats not a lot of money for us but a significant industry game changer. We should double that capital investment in the medium term and conservatively quadruple it in the foreseeable long term. Just to be sure we will give them a 50m loan repayable one day. I will be a hero to many, my ego likes that... (and the peasant will be rich) ... where do i sign.

Hmm...we should first discuss integrity with Alan, and dead wood greedy directors...